



021804

17364 U.S. PTO

PTO/SB/05 (08-03)

Approved for use through 07/31/2006, OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|---|--|--|
| UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i> | | Attorney Docket No. 4303-040164 |
| | | First Inventor Daniel Paris |
| Title | | ANTI-ANGIOGENIC AND ANTI-TUMORAL PROPERTIES OF BETA AND GAMMA SECRETASE INHIBITORS |
| Express Mail Label No. | | EL 971287125 US |

| | |
|--|---|
| APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i> | ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450 |
|--|---|

| | |
|--|---|
| <p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none">- Descriptive title of the invention- Cross Reference to Related Applications- Statement Regarding Fed sponsored R & D- Reference to sequence listing, a table, or a computer program listing appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings <i>(if filed)</i>- Detailed Description- Claim(s)- Abstract of the Disclosure <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <u>12</u>]</p> <p>5. Oath or Declaration [Total Pages <u> </u>]</p> <ul style="list-style-type: none">a. <input type="checkbox"/> Newly executed (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i><ul style="list-style-type: none">i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p> | <p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program <i>(Appendix)</i></p> <p>8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i></p> <ul style="list-style-type: none">a. <input type="checkbox"/> Computer Readable Form (CRF)b. Specification Sequence Listing on:<ul style="list-style-type: none">i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); orii. <input type="checkbox"/> paperc. <input type="checkbox"/> Statements verifying identity of above copies |
|--|---|

ACCOMPANYING APPLICATION PARTS

- | | |
|---|--|
| 9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) | |
| 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> | <input type="checkbox"/> Power of Attorney |
| 11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> | |
| 12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 | <input type="checkbox"/> Copies of IDS Citations |
| 13. <input type="checkbox"/> Preliminary Amendment | |
| 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> | |
| 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> | |
| 16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. | |
| 17. <input checked="" type="checkbox"/> Other: Letter Recognizing Attorneys (2 pp.) | |

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: ____/____

Prior application information: Examiner _____ Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number: 28289 OR ☐ Correspondence address below
(Insert Customer No. or Attach bar code label here)

| | | | | | |
|---------|--|-----------|--------------|----------|--------------|
| Name | Barbara E. Johnson | | | | |
| | Webb Ziesenheim Logsdon Orkin & Hanson, P.C. | | | | |
| Address | 700 Koppers Building | | | | |
| | 436 Seventh Avenue | | | | |
| City | Pittsburgh | State | PA | Zip Code | 15219 |
| Country | United States | Telephone | 412-471-8815 | Fax | 412-471-4094 |

| | | | |
|-------------------|---------------------------|-----------------------------------|--------|
| Name (Print/Type) | Barbara E. Johnson | Registration No. (Attorney/Agent) | 31,198 |
| Signature | <i>Barbara E. Johnson</i> | Date | 2003 |

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

{W0106499.1}

031356 U.S. PTO
10/780905

021804

The PTO did not receive the following listed item(s): Fee Transmittal



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

ATTORNEY'S DOCKET NUMBER

Daniel Paris and
Michael Mullan

4303-040164

ENTITLED

**"ANTI-ANGIOGENIC AND ANTI-TUMORAL PROPERTIES OF
BETA AND GAMMA SECRETASE INHIBITORS"**

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number EL 971287125 US

Date of Deposit February 18, 2004

I hereby certify that the following enclosed papers or fees:

Letter Recognizing Attorneys (2 pp.)
Utility Patent Application Transmittal Letter (1 p.)
Specification (22 pp.), Claims (9 pp.) and Abstract (1 p.); and
Sheets of drawings (12 pp.)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Helen Gerace
(Typed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : Not Yet Assigned

Applicants : Daniel Paris and
Michael Mullan

Filed : Filed Concurrently Here

Title : ANTI-ANGIOGENIC AND ANTI-
TUMORAL PROPERTIES OF BETA AND
GAMMA SECRETASE INHIBITORS

Customer No. : 28289

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

LETTER RECOGNIZING ATTORNEYS

Sir:

Enclosed for filing is an informal application for patent as above identified, comprising a specification, claims, abstract and drawings.

Information regarding the inventors and the application is as follows:

1. Inventors:

Daniel Paris
2040 Whitfield Avenue
Bradenton, Florida 34243; and

Michael Mullan
2040 Whitfield Avenue
Bradenton, Florida 34243

2. Citizenship:

Daniel Paris, citizen of France; and

Michael Mullan, United Kingdom citizen.

3. Title: ANTI-ANGIOGENIC AND ANTI-TUMORAL PROPERTIES OF BETA AND
GAMMA SECRETASE INHIBITORS

4. Priority: United States Provisional Application Number 60/319,954, filed February 18, 2003.

5. Drawings: 12 sheets of drawings containing 10 figures
6. Claims: 49 claims
7. Small Entity: Small Entity Status is asserted for this application under 37 CFR 1.27.


Please accept the application for purposes of granting a filing date pursuant to 37 C.F.R. §1.53(b) and recognize Gwen R. Wood, Registration No. 51,027; Barbara E. Johnson, Registration No. 31,198; Russell D. Orkin, Registration No. 25,363; and Patricia A. Olsky, Registration No. 53,411 as attorneys in this application, pending the filing of a formal Declaration and Power of Attorney and payment of the filing fee. 37 C.F.R. §1.53(f).

Kindly direct all communications relating to this application to Barbara E. Johnson.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By



Barbara E. Johnson
Registration No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: 412-471-8815
Facsimile: 412-471-4094
E-mail: webblaw@webblaw.com